Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

Dave Singh1 Manchester University NHS Foundation Hospital Trust, the University of Manchester, Manchester, UKCorrespondence[email protected]
View further author information

Gerard J Criner2 Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USAView further author information

Alvar Agustí3 Respiratory Institute (Hospital Clinic), IDIBAPS, CIBERES, Catedra Salud Respiratoria (University of Barcelona), Barcelona, SpainView further author information

Mona Bafadhel4 School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UKView further author information

Johan Söderström5 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Gabriela Luporini Saraiva6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

Yue Song6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information

Maria Jison6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information

Ubaldo J Martin6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information

Ioannis Psallidas8 Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.